DANIELI & C/ IT0000076502 /

6/24/2022 5:35:22 PM	Chg. +0.250	Volume	Bid5:55:00 PM	Ask5:55:00 PM	High	Low
20.350EUR	+1.24%	23,664 Turnover: 478,915.850	20.250Bid Size: 300	20.700Ask Size: 130	20.450	20.000

GlobeNewswire 3/21 Precipio Inc. Announces the Resignation of its Chief Financial Officer and Appointment of Interim CF...

GlobeNewswire 2/24 Precipio Releases Year-End 2021 Preliminary Unaudited Results and Outlook for 2022

GlobeNewswire 2/16 Hitachi Energy brings 5G connectivity to mission-critical industrial and utility operations

GlobeNewswire 12/2/2021 Algoma Steel Selects Danieli as Technology Provider for New Electric Arc Steelmaking Facility

GlobeNewswire 11/18/2021 New York State Approves Precipio’s HemeScreen for POL clinical use

GlobeNewswire 8/26/2021 American Oncology Network Partners with Precipio to Bring HemeScreen® into AON’s Laboratory

GlobeNewswire 7/28/2021 Precipio Announces Preliminary Unaudited Q2-2021 Revenues of $2.3M

GlobeNewswire 6/15/2021 Precipio Terminates its Equity Line

GlobeNewswire 6/8/2021 Precipio Launches HemeScreen® Anemia Panel, a One-of-its-Kind Testing Tool

GlobeNewswire 5/10/2021 Precipio Launches New HemeScreen Panel for AML, with an unparalleled 4-hour turnaround-time

GlobeNewswire 5/3/2021 Precipio Launches its Rapid COVID-19 Antibody test on Amazon Platform

GlobeNewswire 4/26/2021 Current Signed Customers Expected to Generate $1M Annualized Reported Revenues from Precipio’s HemeS...

GlobeNewswire 4/5/2021 Precipio Enters Into an At-The -Market (ATM) Financing Arrangement

GlobeNewswire 3/30/2021 Precipio Announces 95% Annual Growth YoY and 180% Quarterly Growth YoY

GlobeNewswire 3/3/2021 Mr. Ron Andrews joins Precipio’s Board of Directors

GlobeNewswire 3/3/2021 Mr. Richard Sandberg is appointed Chairman of Precipio’s Board of Directors

GlobeNewswire 1/28/2021 Precipio Launches COVID-19 Antibody Testing at Point-of-Care

GlobeNewswire 1/20/2021 Precipio Signs HemeScreen™ Deals with Two Leading Oncology Groups

GlobeNewswire 12/10/2020 Precipio Signs Sales & Marketing Agreement for HemeScreen™ with Major Oncology Distributor

GlobeNewswire 10/6/2020 Precipio & ADS Biotec Launch Seven Beta sites for IV-Cell™

GlobeNewswire 9/22/2020 Precipio Launches its Proprietary HemeScreen™ AML (Acute Myeloid Leukemia) Molecular Panel

GlobeNewswire 9/4/2020 Precipio Announces a Shareholder Call to Discuss its COVID-19 Progress and Future Plans

GlobeNewswire 8/20/2020 Precipio & ADS Biotec Sign Global Distribution Agreement for IV-Cell™

GlobeNewswire 8/4/2020 Precipio Launches Covid-19 Antibody Test in its CLIA laboratory

GlobeNewswire 7/30/2020 Precipio Announces Commercial Launch of COVID-19 Antibody Test